⚖️ Regulatory updates

<aside> ⚖️

Recent regulatory updates: January → April 2026

</aside>

🇺🇸 In the US

Three startups received FDA “no questions” letters, confirming GRAS status and clearing the path for US commercialisation:

• All G (Australia) for its bovine lactoferrin produced through precision fermentation.

  • It plans to begin commercial sales in the US within months, with production ramp-up and ongoing discussions with nutrition and supplement companies.

• Amai Proteins (Israel) for its sweet protein, Swellin, produced by precision fermentation.

  • It claims Swellin is ~3,000× sweeter than sugar, enabling 40–70% sugar reduction and can be labelled “serendipity berry sweet protein”.

• Plantible Foods (US) for its Rubisco protein isolated from duckweed.

  • Rubisco protein is approved for use up to 5% across applications including baked goods, dairy alternatives and plant-based meat.

Two startups achieved self-affirmed GRAS status:

• Melt&Marble (Sweden) for MeltyMarble, its fat produced by precision fermentation for plant-based meat and dairy applications.
• Pureture (US) for its yeast-derived functional protein produced through fermentation, enabling commercialisation in the US.

🇸🇬 In Singapore

• Parima, a French startup, obtained regulatory clearance to sell its cultivated duck in Singapore, becoming the first cultivated meat company globally to hold approvals for two species following its chicken approval in 2025.

See regulatory updates of Q4 2025 here

GRAS revision: The US FDA is considering making GRAS notifications mandatory, with a proposed rule under review and a Notice of Proposed Rulemaking expected soon, which could eliminate the self-GRAS pathway.

US states limiting how alternative proteins can be named or sold:

• A US federal court in Texas ruled that the state’s plant-based meat labelling law is unenforceable for violating the First Amendment, finding that it imposed unconstitutional, protectionist restrictions on plant-based product labelling.